Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 56 references it cites were found in a registry or an index; none of the 34 sources its claims cite is checked for support yet.

Allostery governs Cdk2 activation and differential recognition of CDK inhibitors

Open access

Abstract

Cyclin-dependent kinases (CDKs) are the master regulators of the eukaryotic cell cycle. To become activated, CDKs require both regulatory phosphorylation and binding of a cognate cyclin subunit. We studied the activation process of the G1/S kinase Cdk2 in solution and developed a thermodynamic model that describes the allosteric coupling between regulatory phosphorylation, cyclin binding and inhibitor binding. The results explain why monomeric Cdk2 lacks activity despite sampling an active-like state, reveal that regulatory phosphorylation enhances allosteric coupling with the cyclin subunit and show that this coupling underlies differential recognition of Cdk2 and Cdk4 inhibitors. We identify an allosteric hub that has diverged between Cdk2 and Cdk4 and show that this hub controls the strength of allosteric coupling. The altered allosteric wiring of Cdk4 leads to compromised activity toward generic peptide substrates and comparative specialization toward its primary substrate retinoblastoma (RB).

Overview

CoChat Summary

TL;DR

Cdk2 activation is governed by allosteric coupling between A-loop phosphorylation, cyclin binding, and inhibitor binding, with phosphorylation enhancing the cyclin-driven conformational shift ~4-fold. A divergent allosteric hub explains differential recognition of Cdk2 versus Cdk4 inhibitors and Cdk4’s specialization toward RB.

Key findings

  • Monomeric Cdk2 samples the Aloop-out state at 13 ± 6%; the allosteric coupling parameter α for cyclin-driven shift is 9 for unphosphorylated Cdk2 and 36 for phosphorylated Cdk2, indicating phosphorylation increases the shift ~4-fold.
  • Cdk2 samples three Aloop-out states; only Aloop-out3, adopted by phosphorylated Cdk2:cyclinA, forms the peptide substrate binding site and shows appreciable kinase activity, explaining why monomeric pCdk2 remains inactive.
  • Cdk2 inhibitors promote the Aloop-out/αC-in state and show strong binding cooperativity with cyclin: >10-fold in all four cases and 50-fold for flavopiridol binding unphosphorylated Cdk2; palbociclib and ribociclib lack this cooperativity, while abemaciclib behaves like a Cdk2 inhibitor.
  • The Cdk2cdk4hub mutant with saturating cyclinA retains only a minor Aloop-out subpopulation (19 ± 9%); Cdk4’s KM for a short peptide is 8-fold higher than Cdk2’s, and Cdk2 IC50 values show >20-fold discrimination between Cdk2 and Cdk4 inhibitors, whereas Cdk4 does not clearly differentiate them.

Methods

  • Design: solution-state biophysical and biochemical study of human Cdk2 activation, using DEER spectroscopy, PRE NMR, FRET, and kinase activity assays with purified recombinant Cdk2, cyclinA, and RB.
  • Samples: Cys-lite Cdk2 constructs labeled with MTSSL for DEER/PRE or AF488/AF568 for FRET; T160-phosphorylated Cdk2 prepared by coexpression with yeast CAK; inhibitors tested included flavopiridol, roscovitine, AZD5438, dinaciclib, abemaciclib, palbociclib, and ribociclib.
  • Analysis: DEER distance distributions analyzed by Tikhonov regularization and Gaussian fitting; FRET titrations globally fit to an extended allosteric two-state model using Kintek Explorer, with parameters α, β, γ, and δ; kinase assays used ADP Quest and γ-33P radioactivity for IC50 values.

Limitations

  • The paper states that for phosphorylated Cdk2, the allosteric coupling parameter δ was not well constrained in some datasets, so the authors chose not to interpret δ.
  • Evident from the text: all experiments are in vitro with purified recombinant proteins, and no cellular validation of the thermodynamic model or inhibitor conclusions is reported.
  • Evident from the text: inhibitor conclusions are based on a limited panel of seven compounds and specific assays, so broader generality across CDK inhibitors is not established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41589-020-00725-y

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 26 Not checked · 86 Own results and interpretations

56 more claims

Create a free account to see all 112 claims and to verify the 33 references still open.

See all claims — free account
  • It may state two separate claims as one. 44
  • Probably not a substantial claim. 10

Create a free account to see these claims.

Citations

Cites

Show all 56 references

Cited by

See all 66

Metadata

Authors
Majumdar, A., Burban, D. J., Muretta, J. M., Thompson, A. R., Engel, T. A., Rasmussen, D. M., Subrahmanian, M. V., Veglia, G., Thomas, D. D., & Levinson, N. M.
Affiliations
University of Minnesota (US)
Corresponding author
Levinson, Nicholas M.
Venue
Nature Chemical Biology
Published
2021-02-01
Volume
17
Issue
4
Pages
456-464
ISSN
  • 1552-4450 (ISSN-L)
  • 1552-4469
OpenAlex
W3127335683
Cited by
65
References
56
Citations by year
2026: 11 · 2025: 16 · 2024: 7 · 2023: 6 · 2022: 4 · 2021: 21
FWCI
2.42
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Chemical Biology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • University of Minnesota Digital Conservancy (University of Minnesota) (submittedVersion)
Funders
U.S. Department of Health & Human Services | National Institutes of Health (T32 CA009138, T32 GM132029, R01 GM121515)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords
CDK2, CDK4, cyclin-dependent kinases, allosteric communication, kinase activation, cyclin-dependent kinase inhibitors, thermodynamic modeling, retinoblastoma, G1/S transition, cell cycle regulation
MeSH terms
Allosteric Regulation, Allosteric Site, Cell Cycle, Humans, Microtubule-Associated Proteins, Models, Biological, Phosphorylation, Proto-Oncogene Proteins, Cyclins, Cell Cycle Proteins, Cyclin-Dependent Kinases, Cyclin A, Tumor Suppressor Proteins, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Allostery governs Cdk2 activation and differential recognition of CDK inhibitors. https://app.cochat.ai/papers/10.1038/s41589-020-00725-y
The paper
Majumdar, A., Burban, D. J., Muretta, J. M., Thompson, A. R., Engel, T. A., Rasmussen, D. M., Subrahmanian, M. V., Veglia, G., Thomas, D. D., & Levinson, N. M. (2021). Allostery governs Cdk2 activation and differential recognition of CDK inhibitors. Nature Chemical Biology. https://doi.org/10.1038/s41589-020-00725-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.